Evonik is presenting its latest nutraceutical innovations at Vitafoods Europe 2024 in Geneva, Switzerland. With the new concept of AvailOm & Boswellia for joint health, the recent study findings on IN VIVO BIOTIC and the expansion of the Healthberry portfolio to the U.S. market, the company offers advanced, evidence-based food ingredients to boost consumer preferences and distinguish functional food and food supplement brands.
The nutraceutical innovations portfolio at Evonik Health Care features naturally occurring ingredients with scientifically proven health benefits, along with nutraceutical coating technologies that help ensure the health ingredients are released in the human body at the right time and location. As part of the life sciences division, Nutrition & Care, Evonik Health Care focuses on improving health and quality of life. Customers benefit from a tailored offering of ingredients, as well as application and formulation expertise as a system solution.
“Through our dedication to research and innovation, we provide customized nutraceutical ingredients that address unique health requirements, enabling our partners to offer their customers a convenient and elevated nutritional experience that enhances their quality of life,” stated Susanne Pluta, Director of Consumer Products at Evonik Health Care.
Key highlights at Vitafoods Europe 2024
- AvailOm omega-3 powder and Boswellia serrata ingredient concept. This unique combination is targeted for joint health applications. Its efficacy and synergistic mechanism have been proven through in vitro and human intervention studies. The concept combines Evonik’s superior formulation expertise and scientific evidence for efficacy.
- IN VIVO BIOTICS concepts: A recent study showed the superior gluten-degrading efficacy of IN VIVO BIOTICS gluten tolerance, also in comparison to conventional enzyme-based gluten digestion aids.
- Expansion of Healthberry 865/900 to the U.S. market. With the FDA registration of Evonik’s Norwegian facility Medpalett, Healthberry is now sold in bulk to dietary supplement companies with formulation capabilities and partners in the U.S. for further development and commercialization.
About Evonik
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.